Boston Sci acquires tech to treat CTOs

Boston Scientific has acquired two novel technologies to treat peripheral chronic total occlusions (CTOs), which normally can't be treated with standard endovascular devices such as guidewires and other catheter-based technologies. 

In a statement, Boston Scientific says it acquired a re-entry catheter from Israel's S.I. Therapies in November. And it will obtain an intraluminal CTO crossing device through its acquisition of Sunnyvale, CA-based ReVascular Therapeutics. This acquisition is expected to close this month. Worldwide launches of these devices in approved markets are planned later this year. 

Together, the transactions are expected to have an immaterial impact on GAAP and adjusted earnings this year and in 2012, and be accretive thereafter. Transactional financial terms were not disclosed. 

"Having used both devices, I am impressed with their simplicity and effectiveness," explains Dierk Scheinert, Heart Center Leipzig, and Professor of Medicine at the University of Leipzig. "Access to these technologies will greatly enhance therapeutic options and provide physicians with new, intuitive solutions for treating challenging CTOs," Scheinert adds.

"These acquisitions demonstrate our continued strategic execution of realigning and strengthening our portfolio in areas with high-growth potential," says Boston Scientific President and CEO Ray Elliott. "Our Priority Growth Initiatives include peripheral vascular disease, in which a significant number of patients remain undiagnosed or untreated. Addressing these challenges through use of less-invasive devices could greatly improve the care these patients receive." 

Boston Scientific shares were down 0.6 percent to $6.93 in after-hours trading, Dow Jones reports.

- check out the Boston Scientific release
- get more from Dow Jones

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.